Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9005224 | Clinical Therapeutics | 2005 | 12 Pages |
Abstract
This large study, although limited by its open-label design and post hoc analyses, supports the tolerability and effectiveness of 8 weeks of treatment with nizatidine in children aged 5 days through 18 years. AE incidence and severity were as expected for children during the winter season. There was an overall improvement in symptoms and a decrease in antacid use. Formulation did not appear to alter tolerability or effectiveness assessments: the premade solution, extemporaneous solution, and capsule provided comparable symptomatic relief with no disproportionate adverse reactions.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
MD Orenstein, MD Gremse, BS Pantaleon, MBA Kling, PhD Rotenberg,